| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6958335 (Pediatric) | NOVARTIS | Treatment of gastrointestinal stromal tumors |
Jun, 2022
(1 year, 3 months ago) | |
Gleevec is owned by Novartis.
Gleevec contains Imatinib Mesylate.
Gleevec has a total of 1 drug patent out of which 1 drug patent has expired.
Expired drug patents of Gleevec are:
- US6958335*PED
Gleevec was authorised for market use on 10 May, 2001.
Gleevec is available in capsule;oral dosage forms.
The generics of Gleevec are possible to be released after 19 June, 2022.
Drugs and Companies using IMATINIB MESYLATE ingredient
Market Authorisation Date: 10 May, 2001
Treatment: NA
Dosage: CAPSULE;ORAL
How can I launch a generic of GLEEVEC before it's drug patent expiration?
More Information on Dosage
GLEEVEC family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic